Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977001 | 0.86 | MAPT (0.48) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL426613 | 0.85 | KDM4E (0.53) | MAPTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL3620853 | 0.84 | NR1H4 (0.56) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL106530 | 0.84 | ALDH1A1 (0.59) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12244969 | 0.83 | MAPT (0.56) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL19779243 | 0.83 | NR1H4 (0.51) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10212180 | 0.83 | NR1H4 (0.51) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8379806 | 0.82 | TDP1 (0.41) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5367046 | 0.82 | ALDH1A1 (0.40) | NR1H4MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1546640 | 0.82 | CYP2C19 (0.46) | NR1H4MAPTALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924556-A | Spherical magnesium halide adduct and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924555-A | Catalyst component, catalyst system, application of catalyst system and olefin polymerization method | 中国石油化工股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-1960368-B1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2015-05-06 | — | — | EP | disclosed |
| EP-2205564-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| EP-2426109-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2311814-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2011-04-20 | — | — | EP | disclosed |
| US-7851626-B2 | 4,4,5,5, tetrasubstituted imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2130822-A1 | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents | F. Hoffmann-La Roche AG (CH) | 2009-12-09 | — | — | EP | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | DING QINGJIE | 2007-06-07 | — | — | US | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| EP-0986559-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054184-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | NR1H4 3866/4885MAPT 3889/4885ALDH1A1 3990/4885 |
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | RPS4X, RPS4Y1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NR1H4 1267/4885MAPT 4565/4885ALDH1A1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.